Marketing & Sales

Amgen closes acquisition of 20.5% stake in BeiGene for $2.8bn

US-based Amgen has closed the acquisition of a 20.5% stake in Chinese biopharmaceutical firm BeiGene for approximately $2.8bn to support the expansion of its oncology footprint in China.

GSK closes sale of two vaccine brands to Bavarian Nordic

GlaxoSmithKline (GSK) has completed the sale of its travel vaccines Rabipur for rabies, and Encepur for tick-borne encephalitis, to Bavarian Nordic.

AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia

AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).

Amneal to buy generic pharmaceuticals provider AvKAR for $340m

Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of $340m.

AstraZeneca sells US, Canada rights of Seroquel drugs to Cheplapharm

AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.

Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn

Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.

Novartis’ Sandoz to buy Aspen’s Japanese business in $441m deal

Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).

Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates

Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.

AstraZeneca to sell anti-psychotic medicine rights in Europe and Russia for $239m

AstraZeneca has signed an agreement to sell Seroquel medicine rights in Europe and Russia to Cheplapharm Arzneimittel for around $239m.